Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,794 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06126510RecruitingPhase 2
Study of VG161 for advanced bone and soft tissue sarcoma
This trial tests a new virus-based therapy (VG161) injected directly into tumors for people with advanced bone and soft tissue sarcoma that hasn't responded to other treatments. The goal is to see if the virus can shrink tumors and slow the cancer's growth.
BeijingAges 18–75 - NCT06141070RecruitingPhase 3
Adding high-dose radiation to standard treatment for advanced lung cancer
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
GothenburgAges 18 years+ - NCT06167356Recruiting
Bladder cancer relapse and quality of life study after TURBT
This study tracks patients with early-stage bladder cancer after surgery (TURBT) to see how often the cancer returns and how it affects your daily life.
Milan, MIAges 18 years+ - NCT06170489RecruitingPhase 3
Study of JS004 plus toripalimab for Hodgkin lymphoma
This study tests a new combination of two drugs (JS004 plus toripalimab) versus standard chemotherapy for people with Hodgkin lymphoma that no longer responds to PD-1/PD-L1 immunotherapy. The goal is to see if the new combination works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06186609RecruitingPhase 2
PD-1 Inhibitor and Radiation for Elderly Esophageal Cancer
This trial tests whether combining a PD-1 inhibitor (a type of immunotherapy) with radiation therapy can help older adults (70+) with esophageal squamous cell cancer who cannot have surgery. The goal is to see if this treatment is safe and effective for those with limited options.
Nantong, JiangsuAges 70 years+ - NCT06195800Recruiting
Biomarkers after stem cell transplant for neurological diseases
This trial looks at biomarkers (biological signs in your blood) in people with immune-mediated neurological diseases. It compares those getting a stem cell transplant to those on high-efficacy MS treatments to understand how these therapies work.
Sheffield, EnglandAges 16 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06223880RecruitingPhase 4
AXS-05 vs Bupropion to prevent depression relapse
This study tests whether a new drug called AXS-05 can prevent depression from coming back, compared to an older drug called bupropion. If you have major depression and are at risk of relapse, this trial may help you stay well.
Bellflower, CaliforniaAges 18–65 - NCT06233110RecruitingPhase 1
Ruxolitinib and fostamatinib for steroid-resistant chronic GVHD
This study tests two drugs, ruxolitinib and fostamatinib, together for people with chronic graft-versus-host disease (GVHD) that hasn't responded well to steroids. The goal is to see if this combination can better control GVHD.
Durham, North CarolinaAges 18–80 - NCT06244641Recruiting
New Model for Relapse in Alcohol Use Disorder
This study is testing a new way to understand and predict relapse in people with alcohol use disorder. If you're currently hospitalized for this condition, researchers want to learn from your experience to improve care.
Brussels, Brussels CapitalAges 18 years+ - NCT06271018Recruiting
Tocilizumab for Aortitis in Giant Cell Arteritis
This trial tests the drug tocilizumab (Actemra) to see if it helps reduce swelling in the aorta in people with giant cell arteritis (GCA) who are newly diagnosed or have had a flare. It may offer a targeted treatment for aortitis without using high-dose steroids.
ParisAges 18 years+ - NCT06320405RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This trial tests a combination of three drugs—axatilimab, retifanlimab, and paclitaxel—for people with advanced solid tumors that have spread. It aims to see if this combination can shrink tumors or slow their growth, and it is for people who have already tried taxane chemotherapy.
Portland, OregonAges 18 years+ - NCT06746155Recruiting
Predictors of relapse in major depression
This study looks at adults with major depressive disorder who have responded to treatment, to find out what might predict a relapse. You will wear a wrist activity monitor and complete questionnaires.
Calgary, AlbertaAges 18–70 - NCT06340204RecruitingPhase 1
Weekly liposomal irinotecan for advanced Ewing sarcoma
This trial tests a weekly dose of a chemotherapy drug wrapped in liposomes (tiny fat bubbles) for people with Ewing sarcoma that has come back or not responded to standard treatments. The goal is to see if this new form of the drug can help when other options have stopped working.
Jina, ShandongAges 8–40 - NCT06356883RecruitingPhase 2
Two chemo combos for progressing glioblastoma
This trial tests two different combinations of chemotherapy drugs given directly into the artery that feeds the brain tumor. It is for people with glioblastoma (a type of brain tumor) that has continued to grow after standard treatment.
Sherbrooke, QuebecAges 18 years+ - NCT06376721RecruitingPhase 1/Phase 2
Linperlisib combo for advanced NK/T-cell lymphoma
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06379646Recruiting
YTS109 cell therapy for autoimmune disease
This study tests a new cell therapy (YTS109) for people with autoimmune diseases like lupus or Sjogren's syndrome that have not improved or keep coming back after standard treatments. It aims to see if the treatment can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT06389968Recruiting
Light therapy for vision after optic neuritis in MS
This study tests whether light stimulation can help improve vision after optic neuritis in people with multiple sclerosis. It may offer a way to support eye recovery without medication.
Munich, BavariaAges 18–60 - NCT06393816RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC lung cancer
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Aix-en-ProvenceAges 18 years+ - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06421675RecruitingPhase 2
Elranatamab for multiple myeloma that has come back
This trial tests a new drug called elranatamab (given as an outpatient, not in the hospital) for people with multiple myeloma that has come back or stopped responding to several treatments. The goal is to see if taking it less often works well and is safer.
Vancouver, British ColumbiaAges 18 years+ - NCT06456827Recruiting
Bite force and bone changes after braces in different face types
This trial compares how bite force and bone turnover markers change during the retention phase (after braces) in people with high-angle and low-angle face types. It may help understand why some people have more relapse after braces.
Rohtak, HaryanaAges 18–45 - NCT06470321Recruiting
Predictors of nicotine relapse in smokers
This study looks at factors that might predict whether someone will start smoking again after quitting. It is for adults who smoke daily, want to quit, and are not on any medications.
NicosiaAges 18–60
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,794 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.